Approach to stage IV non-small-cell lung cancer: how to select among first-line therapy options?

Area of Science:

• Oncology
• Pulmonology
• Medical Oncology

Background:

• Stage IV non-small-cell lung cancer (NSCLC) presents several first-line systemic therapy choices.
• Tyrosine kinase inhibitors (TKIs) are effective for patients with specific targetable alterations.
• Many NSCLC patients lack TKI-amenable alterations, necessitating alternative treatments.

Purpose of the Study:

• To simplify the decision-making process for selecting first-line systemic therapy in newly diagnosed stage IV NSCLC.
• To guide clinicians in choosing between immunotherapy and chemoimmunotherapy options.
• To review current data and predictive markers for these treatments.

Main Methods:

• Review of current clinical data on first-line immunotherapy and chemoimmunotherapy regimens for stage IV NSCLC.
• Discussion of programmed death ligand-1 (PD-L1) expression cut-points and their influence on treatment selection.
• Examination of molecular markers that may predict response to immunotherapy.

Main Results:

• Highlights data supporting immunotherapy and chemoimmunotherapy as first-line options for advanced NSCLC.
• Discusses the role of PD-L1 expression levels in guiding treatment decisions.
• Touches upon molecular markers that can predict patient benefit from immunotherapy.

Conclusions:

• Provides a practical guide for clinicians to select appropriate first-line immunotherapy or chemoimmunotherapy for stage IV NSCLC patients.
• Aims to optimize treatment selection in the absence of targetable mutations for TKI therapy.